Genelux (GNLX) Competitors

Genelux presently has a consensus target price of $18.00, suggesting a potential upside of 516.44%. Aquestive Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 71.72%. Given Genelux's higher probable upside, equities analysts plainly believe Genelux is more favorable than Aquestive Therapeutics.

In the previous week, Aquestive Therapeutics had 2 more articles in the media than Genelux. MarketBeat recorded 2 mentions for Aquestive Therapeutics and 0 mentions for Genelux. Genelux's average media sentiment score of 0.00 equaled Aquestive Therapeutics'average media sentiment score.

Genelux has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Aquestive Therapeutics has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market.

37.3% of Genelux shares are held by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are held by institutional investors. 7.5% of Genelux shares are held by company insiders. Comparatively, 6.8% of Aquestive Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Genelux has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -137.08%. Aquestive Therapeutics' return on equity of 0.00% beat Genelux's return on equity.

Genelux has higher earnings, but lower revenue than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks.

Genelux has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. Genelux's return on equity of -174.55% beat Prime Medicine's return on equity.

37.3% of Genelux shares are owned by institutional investors. Comparatively, 70.4% of Prime Medicine shares are owned by institutional investors. 7.5% of Genelux shares are owned by company insiders. Comparatively, 16.0% of Prime Medicine shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Genelux currently has a consensus price target of $18.00, suggesting a potential upside of 516.44%. Prime Medicine has a consensus price target of $7.38, suggesting a potential upside of 119.49%. Given Genelux's higher probable upside, equities research analysts clearly believe Genelux is more favorable than Prime Medicine.

Genelux has higher earnings, but lower revenue than Prime Medicine. Genelux is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

In the previous week, Prime Medicine had 2 more articles in the media than Genelux. MarketBeat recorded 2 mentions for Prime Medicine and 0 mentions for Genelux. Genelux's average media sentiment score of 0.00 equaled Prime Medicine'saverage media sentiment score.

Genelux has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.31, indicating that its stock price is 131% more volatile than the broader market.

In the previous week, ProKidney's average media sentiment score of 1.42 beat Genelux's score of 0.00 indicating that ProKidney is being referred to more favorably in the news media.

Genelux presently has a consensus price target of $18.00, indicating a potential upside of 516.44%. ProKidney has a consensus price target of $7.40, indicating a potential upside of 324.07%. Given Genelux's higher possible upside, research analysts plainly believe Genelux is more favorable than ProKidney.

37.3% of Genelux shares are owned by institutional investors. Comparatively, 51.6% of ProKidney shares are owned by institutional investors. 7.5% of Genelux shares are owned by company insiders. Comparatively, 39.8% of ProKidney shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Genelux has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market. Comparatively, ProKidney has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market.

Genelux has a net margin of 0.00% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat Genelux's return on equity.

Genelux has higher earnings, but lower revenue than ProKidney. Genelux is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Genelux has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat Genelux's return on equity.

Genelux presently has a consensus target price of $18.00, suggesting a potential upside of 516.44%. Altimmune has a consensus target price of $15.71, suggesting a potential upside of 429.10%. Given Genelux's higher probable upside, research analysts clearly believe Genelux is more favorable than Altimmune.

Genelux has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Altimmune has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market.

In the previous week, Altimmune had 4 more articles in the media than Genelux. MarketBeat recorded 4 mentions for Altimmune and 0 mentions for Genelux. Altimmune's average media sentiment score of 0.36 beat Genelux's score of 0.00 indicating that Altimmune is being referred to more favorably in the news media.

37.3% of Genelux shares are held by institutional investors. Comparatively, 78.1% of Altimmune shares are held by institutional investors. 7.5% of Genelux shares are held by insiders. Comparatively, 1.6% of Altimmune shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Genelux has higher earnings, but lower revenue than Altimmune. Genelux is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.